eISSN: 2353-9461
ISSN: 0860-7796
BioTechnologia
Current issue Archive About the journal Editorial board Abstracting and indexing Subscription Contact Instructions for authors
1/2019
vol. 100
 
Share:
Share:
more
 
 
abstract:
RESEARCH PAPERS

Construction and expression of indonesian hepatitis B core antigen (HBcAg) in Lactococcus lactis as potential therapeutic vaccine

Rahma Isartina Anwar, Apon Zaenal Mustopa, Ratih Asmana Ningrum, Suharsono Suharsono

BioTechnologia vol. 100 (1) C pp. 37–45 C 2019
Online publish date: 2019/03/27
View full text
Get citation
ENW
EndNote
BIB
JabRef, Mendeley
RIS
Papers, Reference Manager, RefWorks, Zotero
AMA
APA
Chicago
Harvard
MLA
Vancouver
 
The hepatitis B core antigen protein (HBcAg) may induce proliferation of B, T, and cytotoxic T cells; induce immune responses; and provide T-cell resources for antibody responses after vaccination (Freivalds et al., 2011). Thus, HBcAg may be used as a therapeutic vaccine in patients with chronic hepatitis B virus (HBV) infection. This article describes a study on the construction and expression of HBcAg in Lactococcus lactis by the nisin-controlled expression (NICE) system. An HBcAg gene, the HBV subgenotype B3 that is dominant in Indonesia, was successfully cloned into a pNZ8148 vector and resulted in the formation of the transformant L. lactis NZ3900 pNZ818-HBcAg. The HBcAg protein measured 21 kDa. Induction with 10 ng/ml nisin significantly increased the concentration of the expressed protein. Western blotting and dot blot hybridization analysis indicated that the HBcAg proteins confirmed the expression of an antibody, with potential to become an HBV therapeutic vaccine.
keywords:

hepatitis B virus, HBcAg gene, Lactococcus lactis, NICE system

 
Stosujemy się do standardu HONcode dla wiarygodnej informacji zdrowotnej This site complies with the HONcode standard for trustworthy health information: verify here